Is montelukast effective in regression of endometrial implants in an experimentally induced endometriosis model in rats?

Basit Öğe Kaydı
dc.contributor.authorAltinbas, Sadiman Kiykac
dc.contributor.authorTapisiz, Omer Lutfi
dc.contributor.authorCavkaytar, Sabri
dc.contributor.authorSimsek, Gulcin
dc.contributor.authorOguztuzun, Serpil
dc.contributor.authorGoktolga, Umit
dc.date.accessioned2020-06-25T18:15:54Z
dc.date.available2020-06-25T18:15:54Z
dc.date.issued2015
dc.departmentKırıkkale Üniversitesi
dc.descriptionTapisiz, Omer/0000-0002-7128-8086
dc.description.abstractObjective: Montelukast, a selective antagonist of Type 1 cysteinyl leukotriene receptors (CysLT(1)Rs), antagonizes the proinflammatory and proasthmatic activities of CysLT(1)Rs. We investigated the effect of montelukast on a surgically induced endometriosis rat model. Study design: Thirty-two sexually mature, cycling, female Wistar-Albino rats, in which endometriotic implants were surgically induced, were randomly divided into three groups. Group I [Montelukast (M), 10 rats)] was given 1.6 mg/kg/day of oral montelukast sodium. Group II [Leuprolide acetate (L), 11 rats] was given 1 mg/kg single dose of s.c.leuprolide acetate. Group III [Control (C), 11 rats] received saline solution through an orogastric tube and served as controls. After a 3-weeks medication, the rats were sacrificed to investigate the endometriotic implants for size and morphological and histological characteristics, including immunoreactivity of MMP-2 and VEGF. Results: The mean area of implants decreased from 48.2 +/- 24.7 to 293 +/- 15.8 mm(2) in Group I (M) (P = 0.008) and from 62 +/- 32.1 to 39.9 +/- 18.1 mm(2) in Group II(L) (P = 0.003). In Group III (C), the mean area increased from 41.1 +/- 31.1 to 60.4 +/- 37.1 mm(2) (P = 0.025). Histopathological analysis showed statistically significant lower scores in rats treated with montelukast compared to leuprolide and controls. MMP H scores were not different between the groups in both epithelial and stromal MMP-2 immunostaining. VEGF H scores were statistically lower in Group I (M) in epithelial VEGF immunostaining when compared to Group II(L) and Group III (C) (P = 0.006). Conclusion(s): Montelukast may effectively cause a significant decrease in the area of endometriotic implants. (C) 2014 Elsevier Ireland Ltd. All rights reserved.en_US
dc.identifier.citationclosedAccessen_US
dc.identifier.doi10.1016/j.ejogrb.2014.10.026
dc.identifier.endpage12en_US
dc.identifier.issn0301-2115
dc.identifier.issn1872-7654
dc.identifier.pmid25462212
dc.identifier.scopus2-s2.0-84920617330
dc.identifier.scopusqualityQ2
dc.identifier.startpage7en_US
dc.identifier.urihttps://doi.org/10.1016/j.ejogrb.2014.10.026
dc.identifier.urihttps://hdl.handle.net/20.500.12587/6336
dc.identifier.volume184en_US
dc.identifier.wosWOS:000348826200002
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherElsevieren_US
dc.relation.ispartofEuropean Journal Of Obstetrics & Gynecology And Reproductive Biology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectEndometriosisen_US
dc.subjectRaten_US
dc.subjectMontelukasten_US
dc.subjectMMP-2en_US
dc.subjectVEGFen_US
dc.titleIs montelukast effective in regression of endometrial implants in an experimentally induced endometriosis model in rats?en_US
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
Is montelukast effective in regression of endometrial implants in an experimentally induced endometriosis model in rats.pdf
Boyut:
1.6 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin/Full Text
İndir

Koleksiyon

WOS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu